Cyteir

99 Hayden Ave
Lexington, MA 02421

Cyteir is a clinical-stage oncology company dedicated to the development of CYT-0851, an oral investigational drug designed to inhibit monocarboxylate transporters. The company's current focus is on advancing CYT-0851 in combination with capecitabine and gemcitabine through a Phase 1/2 clinical study targeting patients with advanced ovarian cancer.

With a pipeline of novel drug candidates aimed at addressing key vulnerabilities in cancer, Cyteir is committed to pioneering therapeutic solutions for patients in need. Their approach emphasizes leveraging cancer's vulnerabilities as a strength in treatment development.

Generated from the website

Own this business?
See a problem?

You might also like